VivoSeq
Other

Antithrombotic

0

Pipeline Programs

11

Active Trials

0

Companies Involved

Antithrombotic is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

3/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

30

clinical trials

Completed12 · 40%
Recruiting8 · 27%
Unknown status6 · 20%
Not yet recruiting2 · 7%
Active, not recruiting1 · 3%
Terminated1 · 3%

Trial Activity

30 trials

Antithrombotic Strategy for AF Patients With High Risk CAD
Not yet recruiting·YYonsei University·N/A·NCT06866665·1,400 enrolled
Resistance to Antithrombotic Therapy
Completed·MMedical University of Vienna·N/A·NCT00858715·46 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)